When should hypertension be treated and what are the recommended lifestyle modifications and pharmacologic therapy?

When and How to Treat Hypertension

Initiate antihypertensive drug treatment immediately when office BP is ≥140/90 mmHg, combined with lifestyle modifications, regardless of cardiovascular risk level 1.

Treatment Initiation Thresholds

Standard Population

• Start pharmacotherapy at BP ≥140/90 mmHg for all adults, irrespective of cardiovascular disease (CVD) risk 1
• For lower-risk patients at this threshold, attempt 3 months of lifestyle intervention first before adding medications 1
• For high-risk patients (existing CVD, chronic kidney disease, or hypertension-mediated organ damage), start medications immediately at ≥140/90 mmHg 1

High-Risk Populations Requiring Earlier Treatment (BP 130-139/80-89 mmHg)

Start pharmacotherapy after maximum 3 months of lifestyle intervention when BP is ≥130/80 mmHg in:

• Diabetes mellitus 1
• Established CVD (coronary disease, heart failure, stroke) 1, 2
• Chronic kidney disease 1

Special Populations

Pregnancy:

• Gestational hypertension or pre-existing hypertension with organ damage: treat at ≥140/90 mmHg 1
• Uncomplicated chronic hypertension: treat at ≥150/95 mmHg 1
• Emergency hospitalization required at ≥170/110 mmHg 1

Elderly (>80 years):

• Consider treatment only when office systolic BP ≥160 mmHg 2

Lifestyle Modifications (First-Line for All Patients)

The 2024 ESC guidelines elevate lifestyle modification to Class I, Level A evidence 1. Implement these interventions for all patients with elevated BP:

Specific Targets

• Sodium restriction: <2 g/day (ESC 2024) or <6 g/day salt equivalent 1, 3
• Potassium intake: ≥3.5 g/day 1
• Weight reduction: ~1/1 mmHg BP reduction per kilogram lost 4
  • Target BMI <25 kg/m² 3
  • Consider GLP-1 receptor agonists or bariatric surgery when lifestyle alone insufficient 3
• Exercise: ≥150 minutes/week of aerobic activity 5, 3
• Alcohol: Reduce or avoid entirely 5, 3
• Diet: DASH (Dietary Approaches to Stop Hypertension) or Mediterranean diet 3
• Smoking cessation: Mandatory 3

Medications/Substances to Avoid

• NSAIDs (nonsteroidal anti-inflammatory drugs) 5
• Serotonin-norepinephrine reuptake inhibitors 5
• Cocaine and other illicit drugs 5

Pharmacologic Therapy

First-Line Agents

All five major drug classes are recommended as first-line options 6:

• ACE inhibitors (A)
• Angiotensin receptor blockers (A)
• Beta-blockers (B)
• Calcium channel blockers (C)
• Thiazide diuretics (D)

Initial Combination Therapy

Start with combination therapy (preferably single-pill combination) when BP is ≥20/10 mmHg above target 6. This approach reduces systolic BP by an additional -3.99 mmHg compared to separate pills 5.

The preferred initial combination is:

• RAS blocker (ACE inhibitor or ARB) + calcium channel blocker + thiazide diuretic 5

Disease-Specific Considerations

Diabetes:

• Target systolic BP to 130 mmHg and <130 mmHg if tolerated, but not <120 mmHg 1
• In elderly ≥65 years with diabetes: target 130-139 mmHg 1

Chronic Kidney Disease:

• Target systolic BP 130-139 mmHg for most 1
• If eGFR >30 mL/min/1.73 m² and moderate-to-severe CKD: target 120-129 mmHg if tolerated 1
• RAS blockers are specifically recommended for patients with microalbuminuria or proteinuria (superior albuminuria reduction) 1

Heart Failure with Reduced Ejection Fraction (HFrEF):

• Use ACE inhibitor (or ARB if intolerant) or ARNI + beta-blocker + MRA + SGLT2 inhibitor 1

Heart Failure with Preserved Ejection Fraction (HFpEF):

• SGLT2 inhibitors recommended for outcomes improvement 1
• ARBs and/or MRAs may be considered to reduce hospitalizations 1

Blood Pressure Targets

General Population

• Target <140/90 mmHg as minimum for all 1
• Target <130/80 mmHg is increasingly recommended, particularly in:
  • Coronary heart disease 7
  • Heart failure 7
  • Chronic kidney disease 7
  • Post-renal transplant 7
  • Secondary stroke prevention 7
  • Diabetes mellitus 1

Elderly (≥65 years)

• Target systolic BP 130-139 mmHg 1
• Avoid lowering diastolic BP <80 mmHg in pregnant women 1

Resistant Hypertension Management

When BP remains ≥130/80 mmHg despite 3 maximally tolerated antihypertensive medications (including a diuretic):

Exclude First

• White-coat hypertension (37.5% of apparent resistant hypertension) - confirm with home or 24-hour ambulatory BP monitoring 5
• Medication nonadherence (~50% of cases) 5
• Secondary hypertension, especially primary aldosteronism (5-25% of cases) 5

Treatment Optimization

1. Switch to chlorthalidone (more potent than hydrochlorothiazide) 5
2. Add spironolactone 25-50 mg/day if eGFR ≥45 mL/min/1.73 m² and potassium ≤4.5 mmol/L
   • Reduces office systolic BP by -13.3 mmHg 5
   • Reduces 24-hour ambulatory systolic BP by -8.46 mmHg 5
3. Consider renal denervation after multidisciplinary assessment for patients on <3 drugs who prefer this option 1
   • Reduces 24-hour ambulatory systolic BP by -4.4 mmHg 5
   • Not recommended as first-line or if eGFR <40 mL/min/1.73 m² 1

Critical Pitfalls to Avoid

• Do not rely solely on office BP measurements - confirm diagnosis with home BP monitoring (722 protocol: duplicate readings, twice daily, over 7 days) or 24-hour ambulatory monitoring 6
• Do not delay treatment in high-risk patients - immediate pharmacotherapy is warranted at ≥140/90 mmHg in those with CVD, diabetes, or CKD 1
• Do not use monotherapy when BP is ≥20/10 mmHg above target - start with combination therapy 6
• Screen and treat sleep apnea when diagnosed, as it contributes to resistant hypertension 5